| Literature DB >> 32349982 |
Marco Matucci-Cerinic1, Cosimo Bruni2, Yannick Allanore3, Massimo Clementi4,5, Lorenzo Dagna6,7, Nemanja S Damjanov8, Amato de Paulis9, Christopher P Denton10, Oliver Distler11, David Fox12, Daniel E Furst2,13,14, Dinesh Khanna12, Thomas Krieg15, Masataka Kuwana16, Eun Bong Lee17, Mengtao Li18, Shiv Pillai19, Yukai Wang20, Xiaofeng Zeng21, Gloria Taliani22.
Abstract
Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: autoimmune diseases; hydroxychloroquine; scleroderma; systemic
Mesh：
Substances：
Year: 2020 PMID： 32349982 DOI： 10.1136/annrheumdis-2020-217407
Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103